Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viridian Therapeutics Inc (VRDN)

Viridian Therapeutics Inc (VRDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,893,896
  • Shares Outstanding, K 102,207
  • Annual Sales, $ 70,850 K
  • Annual Income, $ -342,600 K
  • EBIT $ -363 M
  • EBITDA $ -370 M
  • 60-Month Beta 1.00
  • Price/Sales 39.51
  • Price/Cash Flow N/A
  • Price/Book 4.43

Options Overview Details

View History
  • Implied Volatility 86.79% (-21.26%)
  • Historical Volatility 119.09%
  • IV Percentile 29%
  • IV Rank 19.90%
  • IV High 214.65% on 03/20/26
  • IV Low 55.02% on 08/08/25
  • Expected Move (DTE 17) 2.27 (11.61%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 370
  • Volume Avg (30-Day) 453
  • Put/Call OI Ratio 1.90
  • Today's Open Interest 12,870
  • Open Int (30-Day) 8,991
  • Expected Range 17.28 to 21.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.04
  • Number of Estimates 7
  • High Estimate $-0.95
  • Low Estimate $-1.20
  • Prior Year $-0.87
  • Growth Rate Est. (year over year) -19.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.97 +15.17%
on 03/30/26
30.79 -36.52%
on 03/05/26
-9.83 (-33.48%)
since 02/27/26
3-Month
16.97 +15.17%
on 03/30/26
34.29 -43.00%
on 01/14/26
-12.33 (-38.69%)
since 12/26/25
52-Week
9.90 +97.42%
on 04/09/25
34.29 -43.00%
on 01/14/26
+5.11 (+35.35%)
since 03/28/25

Most Recent Stories

More News
Stocks Pressured by Economic Fallout from Iran War

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.39%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.78%. June E-mini...

AMAT : 341.79 (+5.78%)
SNDK : 635.34 (+10.98%)
INTU : 432.38 (+0.78%)
$IUXX : 23,740.19 (+3.43%)
LITE : 702.76 (+7.33%)
UTHR : 592.80 (+0.75%)
ASML : 1,320.83 (+5.33%)
ZNM26 : 111-015s (+0.21%)
GLW : 135.97 (+5.77%)
ESM26 : 6,570.75s (+2.86%)
STX : 391.76 (+8.09%)
WDC : 270.49 (+7.48%)
Markets Turn Negative as Crude Oil Prices Surge

The S&P 500 Index ($SPX ) (SPY ) today is down -0.75%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.18%. Stock indexes turned lower...

AMAT : 341.79 (+5.78%)
AVGO : 309.51 (+5.49%)
INTU : 432.38 (+0.78%)
DDOG : 118.05 (+1.93%)
EXPE : 230.89 (+1.93%)
$IUXX : 23,740.19 (+3.43%)
UTHR : 592.80 (+0.75%)
ASML : 1,320.83 (+5.33%)
ZNM26 : 111-015s (+0.21%)
CLK26 : 101.38s (-1.46%)
STX : 391.76 (+8.09%)
WDC : 270.49 (+7.48%)
Stocks Rebound as T-note Yields Tumble

The S&P 500 Index ($SPX ) (SPY ) today is up +0.42%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.32%. June E-mini S&P futures (ESM26...

MSTR : 124.80 (+2.77%)
INTU : 432.38 (+0.78%)
DDOG : 118.05 (+1.93%)
GLXY : 18.45 (+7.58%)
EXPE : 230.89 (+1.93%)
$IUXX : 23,740.19 (+3.43%)
COIN : 174.61 (+8.60%)
UTHR : 592.80 (+0.75%)
ZNM26 : 111-015s (+0.21%)
ESM26 : 6,570.75s (+2.86%)
$DOWI : 46,341.51 (+2.49%)
^BTCUSD : 67,960.59 (-0.35%)
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

- REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved...

VRDN : 19.55 (+5.48%)
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

   - PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch - ...

VRDN : 19.55 (+5.48%)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced...

VRDN : 19.55 (+5.48%)
Viridian Therapeutics Prepares for Transformational 2026

- Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track - - Topline...

VRDN : 19.55 (+5.48%)
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

- PDUFA target action date of June 30, 2026 - - Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement...

VRDN : 19.55 (+5.48%)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced...

VRDN : 19.55 (+5.48%)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced...

VRDN : 19.55 (+5.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed above 20%. The market has bounced from extreme oversold territory, indicating a possible trend reversal.

See More Share

Business Summary

Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.

See More

Key Turning Points

3rd Resistance Point 21.56
2nd Resistance Point 20.33
1st Resistance Point 19.43
Last Price 19.55
1st Support Level 17.30
2nd Support Level 16.07
3rd Support Level 15.17

See More

52-Week High 34.29
Fibonacci 61.8% 24.97
Fibonacci 50% 22.10
Last Price 19.55
Fibonacci 38.2% 19.22
52-Week Low 9.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.